drugset / Trial / NCT05369065

Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities

NCT05369065

Phase 1 Recruiting 60 enrolled Neurotronic, Inc. Libra Medical · collab
NaParallel-groupDouble-blindTreatment

Summary

This study is to assess the safety and performance of the Neurotronic Infusion Catheter and ethanol denervation of renal and hepatic arteries for the treatment of patients with Type 2 Diabetes (T2DM), Hypertension and Obesity.

Timeline

Start
2022-01-27
Primary completion
2025-01
Completion
2029-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Alcohol Other / unclassified